← Back to Search

LPS for Alzheimer's Disease

Phase < 1
Waitlist Available
Led By Adam Mecca, M.D., Ph.D.
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 180 minutes post intervention
Awards & highlights

Study Summary

This trial looks at how well microglia cells work in people with Alzheimer's Disease compared to people with no cognitive problems and to younger people.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~180 minutes post intervention
This trial's timeline: 3 weeks for screening, Varies for treatment, and 180 minutes post intervention for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Microglial Activation Reserve Index (MARI)
Secondary outcome measures
Effects of MARI on Cognition

Side effects data

From 2016 Phase 4 trial • 16 Patients • NCT02875028
53%
headache
27%
Chills
13%
Myalgia
13%
malaise
7%
Dizziness
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
Vorapaxar

Trial Design

1Treatment groups
Experimental Treatment
Group I: Patients receiving endotoxinExperimental Treatment1 Intervention
The 20 enrolled subjects will have LPS (0.4 ng/kg) administered intravenously
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LPS
2018
Completed Phase 4
~230

Find a Location

Who is running the clinical trial?

Yale UniversityLead Sponsor
1,847 Previous Clinical Trials
2,736,510 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,668 Previous Clinical Trials
28,005,046 Total Patients Enrolled
Adam Mecca, M.D., Ph.D.Principal InvestigatorYale University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what extent is this trial being conducted, and how many people are enrolled?

"Affirmative. According to clinicaltrials.gov, this research project is actively seeking participants and was published on April 15th 2018 with their most recent update taking place on February 8th 2022. They are looking for 20 volunteers from a single facility."

Answered by AI

Is it still possible for individuals to register for this research endeavor?

"Affirmative. The information on clinicaltrials.gov verifies that this trial is currently open to participants, having first been posted on April 15th 2018 and most recently updated February 8th 2022. This research endeavour requires 20 volunteers from a single location."

Answered by AI

To what demographic does this research opportunity appeal?

"Qualified applicants for this clinical trial should be between 55 and 90 years old, suffering from Alzheimer's disease. The team is currently looking to enroll 20 individuals."

Answered by AI

Does this research consider individuals of advanced age as potential participants?

"This research is limited to individuals aged 55-90 years old."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Peripheral Benzodiazepine Receptors (PBR28) Brain PET Imaging With Lipopolysaccharide Challenge for the Study of Microglia Function in Alzheimer's Disease
2018. "Peripheral Benzodiazepine Receptors (PBR28) Brain PET Imaging With Lipopolysaccharide Challenge for the Study of Microglia Function in Alzheimer's Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04057807.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top